ASH 2022 Conference Coverage
ASH 2022 Phase 3 ZUMA-7 Trial Updates: Association of Metabolic Tumor Volume and Clinical Outcomes in 2L R/R LBCL Following Axicabtagene Ciloleucel vs. SoC Therapy
By
ASH 2022 Conference Coverage
FEATURING
Frederick L. Locke
By
ASH 2022 Conference Coverage
FEATURING
Frederick L. Locke
Login to view comments.
Click here to Login